Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. Show more

Generaal De Wittelaan L11 A3, Mechelen, 2800, Belgium

https://www.glpg.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

2.257B

52 Wk Range

$22.59 - $37.78

Previous Close

$33.87

Open

$35.73

Volume

258,395

Day Range

$34.31 - $36.22

Enterprise Value

-1.267B

Cash

3.05B

Avg Qtr Burn

-62.61M

Insider Ownership

25.35%

Institutional Own.

22.66%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Jyseleca (Filgotinib) Details Ulcerative colitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Filgotinib Details Axial spondyloarthritis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Filgotinib Details Crohns disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3667 Details Dermatomyositis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3667 Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5101 (CD19 CAR-T) Details Relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5301 BCMA CAR-T Details Multiple myeloma, High Refractory Multiple Myeloma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5201 (CD19 CAR-T) Details Small lymphocytic lymphoma , Chronic lymphocytic leukemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5101 (CD19 CAR-T) Details Systemic lupus erythematosus, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG1205 (GPR84 inhibitor) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3970 (SIK2/3 inhibitor) Details Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ziritaxestat (GLPG1690) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG2737 (CFTR inhibitor) Details Autosomal Dominant Polycystic Kidney Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG4716 (CHIT1/AMCase inhibitor) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.